BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084
262 results:

  • 1. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
    Takei S; Tanaka Y; Lin YT; Koyama S; Fukuoka S; Hara H; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Ueno T; Kojima S; Wakabayashi M; Sakamoto N; Kojima M; Kuwata T; Yoshino T; Nishikawa H; Mano H; Endo I; Shitara K; Kawazoe A
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38336371
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Exploring Co-occurring pole Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
    Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
    Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Caecal malakoplakia: a rare mimic of malignancy.
    Li Voon Chong J; Ali N
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262716
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
    Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
    Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Evaluation of mismatch-repair and microsatellite-instability status in a Chinese colorectal cancer Cohort.
    Zhang P; Wang A; Bian C; Zhang J; Jiang C; Zhou H
    Asian J Surg; 2024 Feb; 47(2):959-967. PubMed ID: 38185557
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A Comprehensive Study of Heterogeneous Mismatch Repair Expression in Solid Tumors Reveals Different Immunohistochemical Patterns and Distinct Genetic Mechanisms.
    Wang J; Zhang Z; Cai Y; Lu J; Zhang H; Pang J; Wu H; Liang Z
    Am J Surg Pathol; 2024 Apr; 48(4):417-425. PubMed ID: 37997470
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
    André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
    JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated pole variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Adoption of Universal Testing in Endometrial cancers for Microsatellite Instability Using Next-Generation Sequencing.
    Rodriguez IV; Strickland S; Wells D; Manhardt E; Konnick EQ; Garcia R; Swisher E; Kilgore M; Norquist B
    JCO Precis Oncol; 2023 Sep; 7():e2300033. PubMed ID: 37856764
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
    Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
    Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
    [No Abstract]    [Full Text] [Related]  

  • 11. Recommendations for the classification of germline variants in the exonuclease domain of pole and POLD1.
    Mur P; Viana-Errasti J; García-Mulero S; Magraner-Pardo L; Muñoz IG; Pons T; Capellá G; Pineda M; Feliubadaló L; Valle L
    Genome Med; 2023 Oct; 15(1):85. PubMed ID: 37848928
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Germline de novo mutations in families with Mendelian cancer syndromes caused by defects in DNA repair.
    Sherwood K; Ward JC; Soriano I; Martin L; Campbell A; Rahbari R; Kafetzopoulos I; Sproul D; Green A; Sampson JR; Donaldson A; Ong KR; Heinimann K; Nielsen M; Thomas H; Latchford A; Palles C; Tomlinson I
    Nat Commun; 2023 Jun; 14(1):3636. PubMed ID: 37336879
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality?
    Vegivinti CTR; Gonzales Gomez C; Syed M; Ferrell M; Cheng S; Singhi A; Saeed A; Sahin IH
    Expert Opin Biol Ther; 2023; 23(7):595-601. PubMed ID: 37318031
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Effect of real-time computer-aided detection of colorectal adenoma in routine colonoscopy (COLO-GENIUS): a single-centre randomised controlled trial.
    Karsenti D; Tharsis G; Perrot B; Cattan P; Percie du Sert A; Venezia F; Zrihen E; Gillet A; Lab JP; Tordjman G; Cavicchi M
    Lancet Gastroenterol Hepatol; 2023 Aug; 8(8):726-734. PubMed ID: 37269872
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. pole-Mutant Colon cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval.
    Bikhchandani M; Amersi F; Hendifar A; Gangi A; Osipov A; Zaghiyan K; Atkins K; Cho M; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hitchins M; Gong J
    Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239414
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910.
    Shida D; Kuchiba A; Shibata T; Hamaguchi T; Yamasaki S; Ito M; Kobatake T; Tonooka T; Masaki T; Shiozawa M; Takii Y; Uetake H; Okamura S; Ojima H; Kazama S; Takeyama H; Kanato K; Shimada Y; Murakami Y; Kanemitsu Y
    Cancer Sci; 2023 Aug; 114(8):3352-3363. PubMed ID: 37189003
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis.
    Garbarino O; Lambroia L; Basso G; Marrella V; Franceschini B; Soldani C; Pasqualini F; Giuliano D; Costa G; Peano C; Barbarossa D; Annarita D; Salvati A; Terracciano L; Torzilli G; Donadon M; Faggioli F
    Aging Cell; 2023 Jul; 22(7):e13853. PubMed ID: 37157887
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Lynch syndrome: influence of additional susceptibility variants on cancer risk.
    Vibert R; Hasnaoui J; Perrier A; Lefebvre A; Colas C; Dhooge M; Basset N; Chansavang A; Desseignes C; Duval A; Farelly S; Hamzaoui N; Laurent-Puig P; Metras J; Moliere D; Muleris M; Netter J; Touat M; Bielle F; Labreche K; Nicolle R; Perkins G; Warcoin M; Coulet F; Benusiglio PR
    Eur J Hum Genet; 2023 Sep; 31(9):1078-1082. PubMed ID: 37088804
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors in pMMR/MSS colorectal cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Pan-cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer.
    Zhong Y; Zheng C; Zhang W; Wu H; Wang M; Zhang Q; Feng H; Wang G
    Front Immunol; 2023; 14():1138077. PubMed ID: 37006282
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 14.